The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

1. ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher
Rates of Treatment
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher
Rates of Treatment
GBI Research, the leading business intelligence provider, has released its latest research: “ADHD
Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of
Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven
major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and
Japan.
The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products
and details of recent industry deals. The report is built using data and information sourced from proprietary
databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry
experts.
The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound
Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are
still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018.
This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.
Scope
Current and future treatment and diagnosis trends for ADHAD Market forecasts for ADHD across seven
major markets Analysis of the developmental pipelines for ADHD Information on recent industry deals
Reasons to Buy
Understand how the ADHD market has developed and is continuing to develop within the featured markets
Predict which products are likely to be most successful in the future Gain an understanding of the possible
market available for specific products
1 Table Of Contents
1.1 List Of Figures
1.2 List Of Tables
2 Attention-deficit Hyperactivity Disorder (adhd) Therapeutics Market To 2018 – Executive Summary
3 Adhd Therapeutics Market To 2018 – Introduction
3.1 Etiology And Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

2. 3.2.1 Child/adult Subpopulations
3.2.2 Male/female
3.3 Diagnosis
3.3.1 Dsm-iv Criteria For Adhd
3.3.1.1 Dsm-v Revision
3.3.2 Icd-10 Criteria For Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues With Diagnosis
3.3.5 Co-morbid Disorders
3.4 Treatment And Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers And Barriers For Adhd Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence Of Adhd
3.5.1.2 Need For Effective Non-stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level Of Co-morbidity
3.6 Report Guidance
4 Adhd Therapeutics: Market Characterization By Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost Of Therapy – Average Of All Major Markets
4.2 The Us
4.2.1 Market Size – The Us
4.2.2 Market Forecast - The Us
4.2.3 Annual Cost Of Therapy – The Us
4.3 Top 5 Countries Of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost Of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost Of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost Of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

3. 4.3.12 Annual Cost Of Therapy – Spain
4.3.13 Market Size – The Uk
4.3.14 Market Forecast – The Uk
4.3.15 Average Annual Cost Of Therapy – The Uk
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost Of Therapy – Japan
5 Adhd Therapeutics Market To 2018 – Competitive Landscape
5.1 Overview Of Major Marketed Products In The Adhd Market
5.1.1 Adderall Xr (mixed Amphetamine Salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate Transdermal Patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate Hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine Hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine Dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine Hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin Xr (dexmethylphenidate Hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

4. 5.1.8.3 Safety
5.1.9 Generic Products
6 Adhdtherapeutics Market To 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 Adhd Therapeutics Pipeline – Pipeline By Phases Of Development
6.3 Trends In The Adhd Therapeutic Pipeline
7 Adhd Therapeutics Market To 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals By Deal Type
7.1.2 Deals By Year
7.1.3 Deals By Geography
7.1.4 Deals By Value
7.2 M&a Landscape
7.2.1 M&a Deals By Deal Type
7.2.2 M&a Deals By Year
7.2.3 M&a Deals By Geography
7.2.4 M&a Deals By Deal Value
7.2.5 Sanofi-aventis Merger, 2004
7.3 R&d Licensing Agreements
7.3.1 Deals By Year
7.3.2 Deals By Geography
7.3.3 Deals By Deals Value
7.3.4 Targacept And Astrazeneca Agreement, 2009
7.4 Co-development Agreements
7.4.1 Deals By Year
7.4.2 Deals By Geography
7.4.3 Deals By Deal Value
7.4.4 Shire And New River Co-development Deal, 2005
8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size By Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

5. 8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment